1. Introduction of sugar-modified nucleotides into CpG-containing antisense oligonucleotides inhibits TLR9 activation.
- Author
-
Yoshida, Tokuyuki, Hagihara, Tomoko, Uchida, Yasunori, Horiuchi, Yoshiyuki, Sasaki, Kiyomi, Yamamoto, Takenori, Yamashita, Takuma, Goda, Yukihiro, Saito, Yoshiro, Yamaguchi, Takao, Obika, Satoshi, Yamamoto, Seiji, and Inoue, Takao
- Subjects
NUCLEOTIDES ,OLIGONUCLEOTIDES ,TOLL-like receptors ,BASE pairs ,DRUG design ,IMMUNE response - Abstract
Antisense oligonucleotides (ASOs) are synthetic single-stranded oligonucleotides that bind to RNAs through Watson–Crick base pairings. They are actively being developed as therapeutics for various human diseases. ASOs containing unmethylated deoxycytidylyl-deoxyguanosine dinucleotide (CpG) motifs are known to trigger innate immune responses via interaction with toll-like receptor 9 (TLR9). However, the TLR9-stimulatory properties of ASOs, specifically those with lengths equal to or less than 20 nucleotides, phosphorothioate linkages, and the presence and arrangement of sugar-modified nucleotides—crucial elements for ASO therapeutics under development—have not been thoroughly investigated. In this study, we first established SY-ODN18, an 18-nucleotide phosphorothioate oligodeoxynucleotide with sufficient TLR9-stimulatory activity. We demonstrated that an unmethylated CpG motif near its 5′-end was indispensable for TLR9 activation. Moreover, by utilizing various sugar-modified nucleotides, we systematically generated model ASOs, including gapmer, mixmer, and fully modified designs, in accordance with the structures of ASO therapeutics. Our results illustrated that introducing sugar-modified nucleotides in such designs significantly reduces TLR9-stimulatory activity, even without methylation of CpG motifs. These findings would be useful for drug designs on several types of ASOs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF